Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas

BMC Cancer

Isabela Martins Gonzaga²  Sheila Coelho Soares-Lima²  Paulo Thiago Souza de Santos²  Tania Cristina Moita Blanco⁵  Bruno Souza Bianchi de Reis⁴  Danielle Carvalho Quintella⁴  Ivanir Martins de Oliveira⁴  Paulo Antonio Silvestre de Faria⁴  Cleber Dario Pinto Kruel¹  Nelson Adami Andreollo³  Tatiana Almeida de Simão⁵  Luis Felipe Ribeiro Pinto⁵ 

[1] Hospital de Clínicas de Porto Alegre, PPG-Ciências Cirúrgicas-Famed, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2400 2o andar, Santana, Porto Alegre, Rio Grande do Sul, CEP: 90035-903, Brazil

[2] Programa de Carcinogênese Molecular, Instituto Nacional de Câncer, Coordenação de Pesquisa, Rua André Cavalcanti, 37 – 6º andar, Bairro de Fátima, Rio de Janeiro, Rio de Janeiro, CEP: 20231-050, Brazil

[3] Departamento de Cirurgia e Gastrocentro, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Rua Alexandre Fleming 181, Barão Geraldo, Campinas, São Paulo, CEP: 13081-970, Brazil

[4] Divisão de Patologia, Instituto Nacional de Câncer, Rua Cordeiro da Graça 156 Santo Cristo, Rio de Janeiro, Rio de Janeiro, CEP: 20.230-240, Brazil

[5] Departamento de Bioquímica, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, Av. 28 de Setembro 87 fundos, Vila Isabel, Rio de Janeiro, CEP: 20551-013, Brazil

关键词: Target therapy;    BRAF;    KRAS;    HER2;    EGFR;    Esophageal cancer;   

Others  :  1134862
DOI  :  10.1186/1471-2407-12-569

 received in 2012-09-07, accepted in 2012-11-29,  发布年份 2012

【 授权许可】

   
2012 Gonzaga et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [2]American Cancer Society: Global cancer facts and figures. Atlanta; 2011.
• [3]McLarty AJ, Deschamps C, Trastek VF, Allen MS, Pairolero PC, Harmsen WS: Esophageal resection for cancer of the esophagus: long-term function and quality of life. Ann Thorac Surg 1997, 63(6):1568-1572.
• [4]Allen JW, Richardson JD, Edwards MJ: Squamous cell carcinoma of the esophagus: a review and update. Surg Oncol 1997, 6:193-200.
• [5]Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C: Validating cancer drug target. Nature 2006, 441:451-456.
• [6]Baselga J: Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001, 19(Suppl 18):41S-44S.
• [7]Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T: Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011, 71(3):249-257.
• [8]Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
• [9]Wong WM: Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract 1999, 7(1):48-50.
• [10]Sergina NV, Moasser MM: The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007, 13(12):527-534.
• [11]Jiang BH, Liu LZ: PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008, 1784(1):150-158.
• [12]Quesnelle KM, Boehm AL, Grandis JR: STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007, 102(2):311-319.
• [13]Molina JR, Adjei AA: The Ras/Raf/MAPK pathway. J Thorac Oncol 2006, 1(1):7-9.
• [14]Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A: The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006, 1766(1):120-139.
• [15]Morgan S, Grandis JR: ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009, 315(4):572-582.
• [16]Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ: Epidermal growth factor receptor mutation testing in the care of lung cancer patient. Clin Cancer Res 2006, 12(14 Pt 2):4403s-4408s.
• [17]Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ: Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11(18):6598-6607.
• [18]Lorenzen S, Lordick F: How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol 2011, 23(4):396-402.
• [19]Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
• [20]Sambrook J, Russell D: Preparation and analysis of eukaryotic genomic DNA. 3rd edition. New York: Cold Spring Harbor Laboratory; 2001:6.1-6.64. [Molecular Cloning – A laboratory Manual, Volume 1]
• [21]Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215.
• [22]Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004, 101(3):13306-13311.
• [23]Robottom Ferreira AB, Ribeiro Pinto LF, Albano RM: An optimized reverse transcription-polymerase chain reaction procedure for the amplification of low copy Cyp2a3 mRNA in rat esophagus. Anal Biochem 2003, 319(2):323-326.
• [24]Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K, Rimm DL: Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 2011, 179(2):580-589.
• [25]Selvarajan S, Bay BH, Chng MJ, Tan PH: The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference? Ann Acad Med Singapore 2004, 33(4):473-476.
• [26]Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O’Byrne KJ: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13(1):33-42.
• [27]Cohen J: Statistical power analysis for the behavioral sciences. New Jersey: Lawrence Erlbaum Associates; 1988.
• [28]Sharafinski ME, Ferris RL, Ferrone S, Grandis JR: Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010, 32(10):1412-1421.
• [29]Mir MM, Dar NA, Salam I, Shah ZA: Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. Int J Health Sci 2008, 2(2):17-25.
• [30]Sunpaweravong P, Suwiwat S, Sunpaweravong S, Puttawibul P, Mitarnun W: Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma. J Med Assoc Thai 2009, 92(9):1136-1142.
• [31]Liu QW, Fu JH, Luo KJ, Yang HX, Wang JY, Hu Y, Yang H, Bella E: Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis Esophagusin press
• [32]Italiano A, Follana P, Caroli FX, Badetti JL, Benchimol D, Garnier G, Gugenheim J, Haudebourg J, Keslair F, Lesbats G, Lledo G, Roussel JF, Pedeutour F, François E: Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008, 15(2):649-654.
• [33]Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S: Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009, 9:303. BioMed Central Full Text
• [34]Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27(35):5924-5930.
• [35]Berardi R, Onofri A, Pistelli M, Maccaroni E, Scartozzi M, Pierantoni C, Cascinu S: Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid 2010, 5:61-76.
• [36]Laurent-Puig P, Lievre A, Blons H: Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009, 15(4):1133-1139.
• [37]Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A: Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 2003, 22(30):4757-4759.
• [38]Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006, 118(5):1173-1180.
• [39]Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC: Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutation. Cancer Res 1991, 51:4102-4106.
• [40]Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19(9):1523-1529.
• [41]Croxtall JD, McKeage K: Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 2010, 70(17):2259-2267.
• [42]Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA: Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009, 9:6. BioMed Central Full Text
• [43]Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL: Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 2012, 29(2):933-940.
• [44]Yarden Y: The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
• [45]Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS: Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res 2006, 66(21):10415-10424.